Literature DB >> 22037622

[Stabilization of inter- and subtrochanteric femoral fractures with the PFNΑ®].

O Büttner1, S Styger, P Regazzoni, N Suhm.   

Abstract

OBJECTIVE: Intramedullary nail system fixation of inter- and subtrochanteric femoral fractures allows early weight-bearing, especially in osteoporotic bone. Restoration of anatomical shape and early return to function of the injured leg. INDICATIONS: All inter- and subtrochanteric fractures of AO type 31-A without limitation. CONTRAINDICATIONS: Open physes and unsuitable femoral shaft anatomy (increased anterior bow of femoral shaft or malunion after femoral fracture). SURGICAL TECHNIQUE: If possible closed, otherwise open fracture reduction on a fracture table and unreamed intramedullary nailing. Fixation of the fracture by insertion of a helical blade via a guide wire in the head-neck fragment of the femur. Option of static or dynamic locking at the femoral diaphysis. POSTOPERATIVE MANAGEMENT: Early mobilization immediately the day after surgery with full weight-bearing and use of assistive device, as tolerated. Thrombosis prophylaxis for 6 weeks with fondaparinux, rivaroxaban or a low molecular weight heparin (LMWH), alternatively oral anticoagulation.
RESULTS: Between April 2004 and June 2005, the AO multicenter study at 11 European trauma centers included 313 patients (mean age 80.6 years, 77% women, 23% men) with 315 unstable trochanteric fractures treated with a Peroximal Femoral Nail Antirotation® (PFNΑ®) device for consecutive follow-up [24]. In 82%, the fractures were 31-A2, while in 18% the fractures were 31-A3. Average operation time for A2 fractures was 56 min and 66 min for A3 fractures. Average duration of hospital stay in the trauma center was 12 days. Surgical reduction and fracture fixation that permitted full weight-bearing immediately after operation was achieved in 72% of cases. Of 165 complications, 46 were surgery-related with unplanned revision surgery in 28 cases (including 7 femur fractures and 4 acetabular penetrations). Follow-up for more than 1 year was possible in 56% of patients. After 1 year, 89% of the fractures were consolidated. The highest complication rate was found in fractures type 31-A2.3 and in patients older than 90 years. The recorded number of implant-related complications (14.6%) is comparable to the results of other intramedullary and extramedullary implants.

Entities:  

Mesh:

Year:  2011        PMID: 22037622     DOI: 10.1007/s00064-011-0030-1

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  28 in total

1.  The new proximal femoral nail antirotation (PFNA) in daily practice: results of a multicentre clinical study.

Authors:  R K J Simmermacher; J Ljungqvist; H Bail; T Hockertz; A J H Vochteloo; U Ochs; Chr v d Werken
Journal:  Injury       Date:  2008-06-25       Impact factor: 2.586

2.  Is the proximal femoral nail a suitable implant for treatment of all trochanteric fractures?

Authors:  Daniel F A Menezes; Axel Gamulin; Bruno Noesberger
Journal:  Clin Orthop Relat Res       Date:  2005-10       Impact factor: 4.176

3.  Helical blade versus sliding hip screw for treatment of unstable intertrochanteric hip fractures: a biomechanical evaluation.

Authors:  Eric Strauss; Joshua Frank; Jason Lee; Frederick J Kummer; Nirmal Tejwani
Journal:  Injury       Date:  2006-08-24       Impact factor: 2.586

4.  Improved intramedullary nail interlocking in osteoporotic bone.

Authors:  K Ito; R Hungerbühler; D Wahl; R Grass
Journal:  J Orthop Trauma       Date:  2001 Mar-Apr       Impact factor: 2.512

5.  The long gamma nail in the treatment of 329 subtrochanteric fractures with major extension into the femoral shaft.

Authors:  R van Doorn; J W Stapert
Journal:  Eur J Surg       Date:  2000-03

6.  Management of fragility fractures in Switzerland: results of a nationwide survey.

Authors:  Norbert Suhm; Olivia Lamy; Kurt Lippuner
Journal:  Swiss Med Wkly       Date:  2008-11-15       Impact factor: 2.193

7.  [Stabilisation of unstable trochanteric femoral fractures. Dynamic hip screw (DHS) with trochanteric stabilisation plate vs. proximal femur nail (PFN)].

Authors:  S Nuber; T Schönweiss; A Rüter
Journal:  Unfallchirurg       Date:  2003-01       Impact factor: 1.000

8.  Biomechanical characterisation of osteosyntheses for proximal femur fractures: helical blade versus screw.

Authors:  Amir A Al-Munajjed; Joachim Hammer; Edgar Mayr; Michael Nerlich; Andreas Lenich
Journal:  Stud Health Technol Inform       Date:  2008

Review 9.  Gamma and other cephalocondylic intramedullary nails versus extramedullary implants for extracapsular hip fractures in adults.

Authors:  Martyn J Parker; Helen H G Handoll
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 10.  Unstable intertrochanteric hip fractures in the elderly.

Authors:  Dieter M Lindskog; Michael R Baumgaertner
Journal:  J Am Acad Orthop Surg       Date:  2004 May-Jun       Impact factor: 3.020

View more
  5 in total

1.  [Repositioning, reduction and surgical approaches for subtrochanteric femoral fractures].

Authors:  B Ulmar; S Simon; I Stratos; T Mittlmeier
Journal:  Unfallchirurg       Date:  2013-12       Impact factor: 1.000

2.  [Cephalomedullary implant using an extension table].

Authors:  G H Sandmann; P Biberthaler
Journal:  Unfallchirurg       Date:  2015-05       Impact factor: 1.000

3.  Trochanteric fragility fractures : Treatment using the cement-augmented proximal femoral nail antirotation.

Authors:  C Neuerburg; S Mehaffey; M Gosch; W Böcker; M Blauth; C Kammerlander
Journal:  Oper Orthop Traumatol       Date:  2016-05-31       Impact factor: 1.154

4.  [Subtrochanteric femoral fractures].

Authors:  B Ulmar; S Simon; A Eschler; T Mittlmeier
Journal:  Unfallchirurg       Date:  2013-12       Impact factor: 1.000

5.  [Surgical revision for complications after gamma3-nailing osteosynthesis of proximal humeral fractures : Follow-up series of 1500 patients].

Authors:  C Hirschfeld; J Jung; A Wicher; M Mousavi
Journal:  Unfallchirurg       Date:  2019-12       Impact factor: 1.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.